Search

Found 33 results

Our Methylome Sequencing Services

Enzymatic Methyl-seq (EM-seq) EM-Seq relies on the NEBNext Enzymatic Methyl-seq kit to enzymatically convert unmethylated cytosines to uracil, preserving the methylated cytosine as cytosine. During PCR, uracil gets converted to thyme. As a result, unmethylated cytosines are sequenced as thyme and methylated cytosines are sequenced as cytosine. This assays allows for the identification of methylated regions at […]

Sample Requirements and Sequencing Information

Whole Genome and Transcriptome Sequencing   WGTSClinical and Research (RUO) WGSClinical and Research (RUO) WTSResearch Only (RUO) pWGSClinical and Research (RUO) Sample Requirements DNA230 ng (gDNA from buffy coat)80 ng (gDNA from fresh frozen)130 ng (gDNA from FFPE) RNA80 ng (RNA from fresh frozen)275 ng (RNA from FFPE) 230 ng (gDNA from buffy coat)80 ng […]

Liquid Biopsy – OMPRN

Learn about a relatively new medical testing technique called liquid biopsy, courtesy of Ontario Molecular Pathology Research Network.

Canadian Bioinformatics Workshop: Bridging Pathology and Genomics: A Practical Workshop on NGS for Pathologists and Pathology Researchers

Toronto, ON October 21-22, 2024 The characterization of sequence variants in a patient’s tumour is key to individualized cancer care. Next-generation sequencing (NGS) is used widely to identify genetic variants in clinical oncology samples. Clinical laboratory professionals and researchers tasked with interpreting molecular results would benefit from understanding the strengths and limitations of the chemical […]

Canadian Bioinformatics Workshop: RNA-seq analysis

Toronto, ON June 17-19, 2024 High-throughput sequencing of RNA libraries (RNA-seq) has become increasingly common and has become the industry standard for transcriptome profiling. When processed appropriately, RNA-seq data has the potential to provide an exceptionally richview of the transcriptome. The CBW has developed a 3-day course providing an introduction to bulk RNA-seq data analysis […]

Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

Cancer Discovery, 14(6), 1048–1063 (2024)

A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer

Clinical Colorectal Cancer, 23(3), 272-284 (2024)

Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.

Cancer Discovery, 14 (1),104–119 (2024)

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

Clinical Cancer Research, 29(18), 3706–3716 (2023)

Transcriptomic changes in liver transplant recipients with non-alcoholic steatohepatitis indicate dysregulation of wound healing

Frontiers in Endocrinology, 14, (2023)